Clinical Trials Logo
  1. Home
  2. Heparin-Induced Thrombocytopenia
  3. NCT00759083

Bivalirudin PCI Registry in Heparin Induced Thrombocytopenia/Heparin Induced Thrombocytopenia and Thrombosis Syndrome (HIT/HITTS) Patients

Heparin-Induced Thrombocytopenia Clinical Trial

Official title:
Bivalirudin PCI Registry in HIT/HITTS Patients

Clinical Trial Summary

To monitor the frequency of the development of thrombocytopenia in patients with Heparin Induced Thrombocytopenia/Heparin Induced Thrombocytopenia and Thrombosis Syndrome receiving bivalirudin during Percutaneous Coronary Intervention

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT00759083
Study type Interventional
Source The Medicines Company
Contact
Status Withdrawn
Phase Phase 4
Start date September 2008
Completion date May 10, 2010
View Details
See also
  Status Clinical Trial Phase
Completed NCT00412464 - Pilot Dose Finding and Pharmacokinetic Study of Fondaparinux in Children With Thrombosis Phase 1
Completed NCT00456326 - Heparin-Induced Thrombocytopenia Registry N/A
Terminated NCT00673439 - Fondaparinux for the Treatment of Heparin-Induced Thrombocytopenia (HIT) Phase 2
Active, not recruiting NCT00198575 - A Study on the Prevalence of Heparin-Induced Thrombocytopenia in Cardiovascular Patients N/A
Completed NCT00283322 - Heparin Antibodies in Intensive Care Unit Patients (HAICU) N/A
Not yet recruiting NCT05586854 - Multicenter Study on Dialysis Modalities for End-stage Chronic Renal Failure Patients With Heparin-induced Thrombocytopenia N/A
Not yet recruiting NCT03269019 - Thrombotic Biomarkers to Predict Thrombosis in Heparin-induced Thrombocytopenia N/A
Not yet recruiting NCT06066762 - Argatroban Monitoring in Acute Suspected Heparin-induced Thrombocytopenia.
Terminated NCT03809481 - Open-Label, Randomised, Active Controlled, Multi-Centre Phase 3 Study Safety and Efficacy of Danaparoid vs Argatroban Phase 3
Completed NCT05325346 - A Phase I Study of the Co-administration of VLX-1005 and Argatroban in Healthy Human Subjects Phase 1
Recruiting NCT02717039 - Pharmacogenomics of Heparin-Induced Thrombocytopenia
Completed NCT02526485 - Immunogenetics of Heparin-Induced Thrombocytopenia: Aim 2
Completed NCT00748839 - Heparin-Induced Thrombocytopenia: Development and Validation of a Predictive Clinical N/A
Recruiting NCT05783895 - Comparison of Pre-test Probability Model for Heparin-induced Thrombocytopenia in Post-operative Cardiac Surgery
Not yet recruiting NCT04782843 - Evaluation of the Intra-observer Agreement of the HEP Score in Surgical Intensive Care.
Completed NCT00198588 - Efficacy and Safety Study of Argatroban to Treat Heparin-Induced Thrombocytopenia Phase 3
Recruiting NCT04842760 - PLATELET Function Assay With Flow Imaging on ImageSTREAM Cytometer
Terminated NCT01598168 - Rivaroxaban for Treatment of Patients With Suspected or Confirmed Heparin-Induced Thrombocytopenia Phase 3
Completed NCT01654848 - Heparin-induced Thrombocytopenia (HIT II) in Liver Transplant Recipients N/A
Withdrawn NCT00603824 - Fondaparinux in Patients With Acute Heparin-Induced Thrombocytopenia (HIT) Phase 4